Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shervin Assassi

Showing results (131-140 of 238) with videos related to

Pageof 24
Sort By:
Annals of the Rheumatic Diseases|June 5, 2026
Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variantBrian Skaug, Stefano Rodolfi, Christopher P Denton, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Arthritis Care & Research|March 14, 2022
Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis CohortsNancy Wareing, Vishnu Mohan, Rana Taherian, et al.
Seminars in Arthritis and Rheumatism|March 25, 2011
Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohortRoozbeh Sharif, Maureen D Mayes, Perry M Nicassio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 3, 2017
CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent CohortsMinghua Wu, Murray Baron, Claudia Pedroza, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 18, 2018
The Antifibrotic Effect of A<sub>2B</sub> Adenosine Receptor Antagonism in a Mouse Model of Dermal FibrosisHarry Karmouty-Quintana, Jose G Molina, Kemly Philip, et al.
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
The Journal of Rheumatology|April 17, 2013
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?Mona Elhaj, Julio Charles, Claudia Pedroza, et al.
Clinical Rheumatology|December 29, 2012
Clinical and serological features of systemic sclerosis in a Chinese cohortJiucun Wang, Shervin Assassi, Gang Guo, et al.
Pageof 24

Showing results (131-140 of 238) with videos related to

Sort By:
Pageof 24
Annals of the Rheumatic Diseases|June 5, 2026
Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variantBrian Skaug, Stefano Rodolfi, Christopher P Denton, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Arthritis Care & Research|March 14, 2022
Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis CohortsNancy Wareing, Vishnu Mohan, Rana Taherian, et al.
Seminars in Arthritis and Rheumatism|March 25, 2011
Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohortRoozbeh Sharif, Maureen D Mayes, Perry M Nicassio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 3, 2017
CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent CohortsMinghua Wu, Murray Baron, Claudia Pedroza, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 18, 2018
The Antifibrotic Effect of A<sub>2B</sub> Adenosine Receptor Antagonism in a Mouse Model of Dermal FibrosisHarry Karmouty-Quintana, Jose G Molina, Kemly Philip, et al.
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
The Journal of Rheumatology|April 17, 2013
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?Mona Elhaj, Julio Charles, Claudia Pedroza, et al.
Clinical Rheumatology|December 29, 2012
Clinical and serological features of systemic sclerosis in a Chinese cohortJiucun Wang, Shervin Assassi, Gang Guo, et al.
Pageof 24